
Sign up to save your podcasts
Or


Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include:
Presenters:
Jesus Berdeja, MD
Amrita Krishnan, MD, FCAP
Content based on an online CME program supported by an educational grant from Johnson & Johnson.
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Decera Clinical Education4.9
1010 ratings
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include:
Presenters:
Jesus Berdeja, MD
Amrita Krishnan, MD, FCAP
Content based on an online CME program supported by an educational grant from Johnson & Johnson.
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

78,636 Listeners

37,636 Listeners

43,528 Listeners

319 Listeners

506 Listeners

57 Listeners

3,360 Listeners

111,948 Listeners

47 Listeners

51 Listeners

59 Listeners

34 Listeners

195 Listeners

46 Listeners